The use of extended release bupivacaine with transversus abdominis plane and subcostal anterior quadratus lumborum catheters: A retrospective analysis of a novel technique

Hesham Elsharkawy1,2, Wael Saasouh2,3, Yoon Jeong Cho4, Loran Mounir Soliman4, Jean‑Louis Horn5
1Case Western Reserve University, 2Outcomes Research Consortium, Cleveland Clinic, Cleveland, OH, 3Department of Anaesthesiology, Detroit Medical Centre, Detroit, MI, 4Department of General Anaesthesiology, Cleveland Clinic, Cleveland, OH, 5Department of Anaesthesiology, Stanford University, Stanford, CA, USA

Abstract

Background and Aims: Liposomal bupivacaine (LB) is a formulation of local anesthetic that may exert analgesia over a prolonged period. Anecdotal use of LB suggests benefit and prolonged analgesia when used to supplement infiltration blocks. Our aim was to test the effect of a bolus of LB delivered through a nerve catheter in two types of interfascial plane blocks (transversus abdominis plane and anterior subcostal quadratus lumborum). The effect was evaluated through patient self-reporting of postsurgical pain up to 48 postoperative hours.

Material and Methods: Medical records of adult postoperative patients who received LB in a peripheral nerve catheter were followed retrospectively and analysed for pain scores and spread of dermatomal numbness over 48 h following the postoperative dose. A chart review of patients who qualified between June 2015 and March 2017 was performed, and clinical data were obtained from the institutional Perioperative Health Documentation System.

Results: Pain scores decreased following LB bolus, and all patients reported efficient block analgesia after bolus injection. Dermatomal numbness decreased gradually and was minimal by 48 h following bolus.

Conclusion: LB can be injected through a peripheral nerve catheter to prolong analgesia after catheter removal.

Keywords: Liposomal bupivacaine, nerve block catheters, postoperative pain, quadratus lumborum block, transversus abdominis plane block

Introduction

Postoperative pain remains a concern following surgery and is a source of morbidity, increased hospital stay, and dissatisfaction.1‑5 Peripheral nerve catheters are currently being used in transversus abdominis plane (TAP) blocks and quadratus lumborum (QL) blocks.1,4,6,7

Liposomal bupivacaine (LB) has been used to increase the duration of postoperative analgesia.8,10 However, published data are insufficient,11,12 and current experience is limited to surgical site infiltration and single‑injection nerve blocks.2,9,13,14 To date, LB has not been used in nerve catheters. We have conducted a retrospective review of analgesia and dermatomal distribution after LB injection in TAP or QL catheters prior to removal.

Material and Methods

The institutional review board at our institution approved...
the study and waived the requirement for written informed consent. The procedures followed were in accordance with the ethical standards of the institution and with the Declaration of Helsinki of 1975, as revised in 2000. We reviewed the charts of all adult patients (≥18 years of age) who received LB injected in peripheral nerve catheters (TAP or QL) between June 2015 and March 2017. Clinical data were obtained from the electronic medical records in the institutional Perioperative Health Documentation System. As this was a retrospective chart review without a control group, no formal statistical power analysis was performed. The medical records of all patients receiving LB through peripheral nerve catheters during this period were included in an LB registry and reviewed in detail. Data were collected by obtaining notes by surgeons, pain team physicians, and ward nurses, as well as electronically uploaded vital signs. Collected data included patient demographics, surgical details (type of procedure, type of peripheral nerve catheter), and catheter insertion details (time of catheter initiation, completion, discontinuation, time of LB bolus). Data were de-identified and stored in an electronic spreadsheet where simple descriptive statistics were calculated (median, range, percentage) and reported as tables and column charts.

The techniques for TAP block, QL block, and catheter insertions have been described elsewhere. Local anaesthetic spread was confirmed on ultrasound imaging in all patients [Figure 1]. All catheters were confirmed to be functional at the time of insertion by observing analgesia and a corresponding dermatomal decreased sensation (T10–T12 for TAP blocks and T8–L1 for QL blocks).

On the day of anticipated catheter removal, the ropivacaine infusion was stopped and patients were observed for 4 h to determine their pain levels and need for further analgesic management. At the end of this observation period, if a patient reported a pain score of 5 or more on the visual analog scale (VAS), they were selected to receive LB through the catheter(s). For patients who received QL catheters, a normal motor examination (hip and knee flexion and extension) was documented prior to LB injection to minimize the risk of falls after discharge. The catheters were first flushed with 10 mL of normal saline to wash out any residual ropivacaine and prevent solution mixing, and then LB was injected once just before removal. For unilateral catheters, 20 mL of LB was injected corresponding to 266 mg (Exparel; Pacira Pharmaceuticals, Parsippany, NJ, USA) diluted with normal saline for a total volume of 30 mL. For bilateral catheters, each side received 10 mL of LB corresponding to 133 mg diluted with normal saline to a total volume of 20 mL. The patients were then observed for at least 4 h prior to hospital discharge and received phone follow-up 24 and 48 h after hospital discharge. This follow-up period was chosen to minimize phone calls to patients (one phone call per day over 2 days) and because it was anticipated that the majority of patients would have experienced their most severe pain within that period.

The pain scores prior to and following LB injection through the catheter (for 48 h after LB) were reported by patients on a 10-point standard pain scale (where 0 indicates no pain, 5 indicates moderate pain, and 10 indicates severe pain).

We asked each patient to report the degree of numbness in the dermatome blocked by the catheter starting from the time of LB injection and over the following 48 h. Patients scored the dermatomal spread at 100% on the day of LB injection, corresponding to maximal analgesic effect and block coverage. We maintained the same method of subjective reporting by patients throughout the study period.

Pain tolerance was another subjective measure that was collected over the study period. Pain tolerance was defined as the comfort of each patient with their pain at predefined intervals: prior to the LB bolus, within 1 h after LB bolus, at 24 h, and at 48 h. An experienced provider from the acute pain team ensured proper removal of all catheters.

**Results**

We included a total of 10 patients in this cohort [Table 1], 7 of whom received TAP blocks (5 unilateral and 2 bilateral) and 3 received QL blocks (1 unilateral and 2 bilateral). Catheters were infused with ropivacaine (0.1% or 0.2%) for the duration of their placement. Each of the peripheral nerve catheters was used for a period of at least 2 days (median 3, range 2–10) depending on the surgical procedure and the status of the patient [Table 2].

Figure 2 shows the baseline median VAS pain scores preceding the bolus injection. All patients reported a decrease in pain on
the bolus day within 1 h of the bolus injection (roughly two points on the VAS scale). Pain scores remained below the baseline levels throughout the study period (48 h following the bolus).

Subjective pain tolerance as described by patients is reported in Table 3. All patients reported being comfortable with their analgesia on the bolus day and at least 24 h later. Some of the patients had acceptable analgesic effect till 48 h after the bolus.

Figure 3 shows the presence of dermatomal numbness as reported by patients. Maximal dermatomal spread was rated at 100% on the day of bolus injection, indicating the patient could feel the numbness in the intended dermatomal distribution.

No patient experienced untoward side effects or complications while in the hospital or after discharge.

Discussion

This novel application of LB and its effects on postoperative pain could complement peripheral nerve catheters and affect patient recovery after catheter removal and discharge.

Table 1: Patient demographics

| ID  | Gender | BMI | Age (years) | Height (cm) | Weight (kg) |
|-----|--------|-----|-------------|-------------|-------------|
| 1   | Female | 22.4| 58          | 157.5       | 59.0        |
| 2   | Male   | 22.0| 23          | 190.5       | 80.0        |
| 3   | Female | 34.2| 57          | 162.6       | 90.4        |
| 4   | Male   | 24.9| 68          | 170.2       | 72.1        |
| 5   | Female | 27.9| 44          | 167.6       | 78.4        |
| 6   | Male   | 21.5| 76          | 165.0       | 58.6        |
| 7   | Female | 36.2| 44          | 157.5       | 89.8        |
| 8   | Female | 29.7| 46          | 156.8       | 73.1        |
| 9   | Female | 24.3| 52          | 163.8       | 65.3        |
| 10  | Male   | 28.0| 55          | 179.0       | 89.8        |

BMI=body mass index

Table 2: Block-related demographics

| ID  | BMI  | Procedure        | Chronic pain* | Block type | Catheter drug†  | Catheter discontinued (POD)‡ |
|-----|------|------------------|---------------|------------|-----------------|-------------------------------|
| 1   | 22.4 | Laparotomy       | Y             | Bilateral TAP | Ropivacaine 0.2% | 10                            |
| 2   | 22.0 | Proctectomy      | N             | Bilateral QL | Ropivacaine 0.2% | 3                             |
| 3   | 34.2 | Laparotomy       | Y             | Bilateral QL | Ropivacaine 0.2% | 6                             |
| 4   | 24.9 | Nephrectomy      | N             | Unilateral TAP | Ropivacaine 0.2% | 2                             |
| 5   | 27.9 | Gastrectomy      | Y             | Bilateral TAP | Ropivacaine 0.1% | 5                             |
| 6   | 21.5 | Kidney transplant| N             | Unilateral TAP | Ropivacaine 0.1% | 3                             |
| 7   | 36.2 | Kidney transplant| N             | Unilateral TAP | Ropivacaine 0.2% | 2                             |
| 8   | 29.7 | Gastric bypass   | Y             | Unilateral TAP | Ropivacaine 0.2% | 7                             |
| 9   | 24.3 | Unilateral hip replacement | Y | Unilateral QL | Ropivacaine 0.2% | 2                             |
| 10  | 28.0 | Laparoscopy      | Y             | Unilateral TAP | Ropivacaine 0.2% | 2                             |

BMI=body mass index, TAP=transversus abdominis plane, QL=quadratus lumborum, POD=postoperative day. *Chronic pain: diagnosis present on admission. †TAP catheters are typically infused at 8-12 mL/h; QL catheters are typically infused at 6-8 mL/h. On the day the peripheral nerve catheter was discontinued, a bolus dose of LP (Exparel; Pacira Pharmaceuticals) was delivered as follows: For unilateral catheters, 266 mg Exparel in 30 mL normal saline. For bilateral catheters, 133 mg Exparel in 20 mL normal saline per side.

The catheters were flushed with normal saline prior to LB injection to avoid a possible rapid release of bupivacaine from the liposomes due to solvent mixing and interactions.[18] As such, it has been recommended to space the two medications over 20–30 min to avoid this interaction and to avoid the use of bupivacaine HCl for several days afterward due to the prolonged half-life of LB.[19]

The available data in this cohort, while not extensive, indicate a trend toward decreasing pain in the 2 days following catheter removal. Patients are typically titrated to a “comfortable” level of analgesia before catheter removal, at which time they are being prepared for hospital discharge.

The heterogeneity of our case series and the absence of a control group preclude firm conclusions, but all our patients...
Elsharkawy, et al.: Extended release bupivacaine with transversus abdominis plane and subcostal anterior quadratus lumborum catheters

Table 3: Patient-reported pain tolerance over 48 h following LB bolus

| Patient | Evaluation within 1 h following LB bolus | 24-h follow-up | 48-h follow-up |
|---------|------------------------------------------|----------------|----------------|
| 1       | Pain well-tolerated                      | Pain well-tolerated | Pain increased at 36 h |
| 2       | Pain well-tolerated                      | Pain well-tolerated | Pain increased at 48 h |
| 3       | Pain well-tolerated                      | Pain well-tolerated | Pain increased at 36 h |
| 4       | Pain well-tolerated                      | Pain well-tolerated | Pain increased at 48 h |
| 5       | Pain well-tolerated                      | Pain well-tolerated | Pain increased at 48 h |
| 6       | Pain well-tolerated                      | Pain well-tolerated | Pain increased at 48 h |
| 7       | Pain well-tolerated                      | Pain well-tolerated | Pain increased at 48 h |
| 8       | Pain well-tolerated                      | Pain well-tolerated | Pain increased at 48 h |
| 9       | Pain well-tolerated                      | Pain well-tolerated | Pain increased at 48 h |
| 10      | Pain well-tolerated                      | Pain well-tolerated | Pain increased at 36 h |

LB=Liposomal bupivacaine. Pain tolerance was defined as the comfort of each patient with their pain at predefined study intervals (subjective reporting, qualitative measure). Patients were discharged home following a 4-h observation period after the LB bolus. Follow-up phone calls were made over the 2 days following the LB bolus.

Figure 3: Presence of dermatomal numbness (decreasing from 100%) as reported by patients starting from LB bolus and over the following 48 h. Analgesic effect differed by type and laterality of block. Most patients reported nonsignificant numbness (20% or less) at 48 h after the LB bolus. LB = liposomal bupivacaine, Bil = bilateral, Uni = unilateral, TAP = transversus abdominis plane, QL = quadratus lumborum

| Block type   | Numbness present (decreasing from 100) |
|--------------|----------------------------------------|
|              | Bolus day | 24 h | 36 h | 48 h |
| Uni TAP (total of 5) | 100 | 60 | 20 | 0 |
| Bil TAP (total of 2) | 100 | 100 | 50 | 50 |
| Uni QL (total of 1) | 100 | 100 | 100 | 0 |
| Bil QL (total of 2) | 100 | 50 | 0 | 0 |
| All (total of 10) | 100 | 70 | 30 | 10 |

reported good pain control on the day of LB bolus and throughout the next day.

The use of LB in QL blocks is novel, with the first case report published in 2016 and describing an anterior QL block achieving sensory blockade for 2 days. Three later reports described reduced postoperative pain, enhanced ambulation, and decreased overall cost with the use of LB postoperatively. However, these reports consisted of two case series with no control and a retrospective analysis with propensity matching. Indwelling catheters are neither without complications nor without risks. Two recent reviews have discussed the complications of peripheral nerve catheters including infection, secondary block failure, catheter migration, obstruction, kinking, infusion pump malfunction, and inadvertent catheter removal. Application of LB in peripheral nerve catheters may prove helpful for procedures with short hospital stay where patients can have significant pain at the time of scheduled discharge, or in cases where anticoagulation needs to be resumed in the early postoperative period precluding the ability to keep a catheter in place.

QL blocks can be associated with muscle weakness. A recent report mentions unilateral hip flexion and knee extension weakness for 18 h following lateral QL block with 20 mL of levobupivacaine 0.25%. It is probable that the weakness resulted from local anaesthetic spread to the L1, L2, and branches of the lumbar plexus. We did not find any muscle weakness in our patients, whether before or after the LB injection.

The cost of liposome bupivacaine is one factor that deters hospitals from using it routinely. The overall cost of prolonged hospitalization and readmission secondary to pain and opioid-related complications, however, may exceed the cost for patients receiving LB. This cost should also take into account the requirement to follow-up with patients for up to 3 days postoperatively and assess their pain and possible adverse effects. A cost-effectiveness analysis needs to be conducted.

A formal prospective, randomized, blinded controlled trial with placebo and/or plain bupivacaine is necessary to define the real value of the technique.

Financial support and sponsorship
Nil.

Conflicts of interest
Dr. Elsharkawy has received unrestricted educational funding from PAJUNK Medical Systems (Norcross, GA,
References

1. Shaaban M, Esa WA, Maheshwari K, Elsharkawy H, Soliman LM. Bilateral continuous quadratus lumborum block for acute postoperative abdominal pain as a rescue after opioid-induced respiratory depression. A A Case Rep 2015;5:107-11.

2. Beaussier M, Sciard D, Sautet A. New modalities of pain treatment after outpatient orthopaedic surgery. Orthop Traumatol Surg Res 2016;102:S121-4.

3. Elsharkawy H, Maheshwari A, Farag E, Mariano ER, Rosenquist RW. Transversus abdominis block: Anatomical concepts, mechanisms, and future perspectives. Pain Pract 2013;13:332-44.

4. Taylor R, Pergolizzi JV, Sinclair A, Raffa RB, Aldington D, Plavin S, et al. Transversus abdominis block: Clinical uses, side effects, and future perspectives. Pain Pract 2013;13:332-44.

5. Jöhr M. Regional anaesthesia in neonates, infants and children. Eur J Anaesthesiol 2016;30:138-47.

6. Blanco R, Ansari T, Girgis E. Quadratus lumborum block for postoperative pain after caesarean section: A randomised controlled trial. Eur J Anaesthesiol 2015;32:812-8.

7. Elsharkawy H, El-Boghdadly K, Barrington M. Quadratus Lumborum Block: Anatomical Concepts, Mechanisms, and Techniques. Anesthesiology 2019;130(2):322-335.

8. Fayezizadeh M, Petro CC, Rosen MJ, Novitsky YW. Enhanced recovery after surgery pathway for abdominal wall reconstruction: Pilot study and preliminary outcomes. Plast Reconstr Surg 2014;134:151S-9S.

9. Vyas KS, Rajendran S, Morrison SD, Shakir A, Mardini S, Lemaine V, et al. Systematic review of liposomal bupivacaine (Exparel) for postoperative analgesia. Plast Reconstr Surg 2016;138:748e-56e.

10. Ma J, Zhang W, Yao S. Liposomal bupivacaine infiltration versus femoral nerve block for pain control in total knee arthroplasty: A systematic review and meta-analysis. Int J Surg 2016;36:44-55.

11. Hamilton TW, Athanassoglou V Trivella M, Strickland LH, Mellon S, Murray D, et al. Liposomal bupivacaine peripheral nerve block for the management of postoperative pain. Cochrane database Syst Rev 2016;CD011476. doi: 10.1002/14651858.CD011476.pub2.

12. Uskova A, O’Connor JE. Liposomal bupivacaine for regional anesthesia. Curr Opin Anaesthesiol 2015;28:593-7.

13. Morales R Jr, Mentz H 3rd, Newall G, Patronella C, Masters O 3rd, Use of abdominal field block injections with liposomal bupivacaine to control postoperative pain after abdominoplasty. Aesthet Surg J 2013;33:1148-53.

14. Vandepitte C, Kuroda M, Witvrouw R, Anne L, Bellemans J, Corten K, et al. Addition of liposome bupivacaine to bupivacaine HCl versus bupivacaine HCl alone for interscalene brachial plexus block in patients having major shoulder surgery. Reg Anesth Pain Med 2017;42:334-41.

15. McDonnell JG, O’Donnell B, Curley G, Heffernan A, Power C, Laffey JG. The analgesic efficacy of transversus abdominis plane block after abdominal surgery: A prospective randomized controlled trial. Anesth Analg 2007;104:193-7.

16. Elsharkawy H, DeGrande S, Ahuja S, Maheshwari K, Chan V. Subcostal Approach to Anterior Quadratus Lumborum Block for Pain Control Following Open Urological Procedures. Journal of Anesthesia J 2019;33:148.

17. Elsharkawy H, El-Boghdaddy K, Kolli S, Esa WAS, DeGrande S, Soliman LM, et al. Injectable spread following anterior sub-costal and posterior approaches to the quadratus lumborum block: A comparative cadaveric study. Eur J Anaesthesiol 2017;34:587-95.

18. Kharitonov V. A review of the compatibility of liposome bupivacaine with other drug products and commonly used implant materials. Postgrad Med 2014;126:129-38.

19. Lonner JH, Scuderi GR, Lieberman JR. Potential utility of liposome bupivacaine in orthopedic surgery. Am J Orthop (Belle Mead NJ) 2015;44:111-7.

20. Elsharkawy H, Salmasi Y, Soliman LM, Esa WAS, Blanco R. Anterior quadratus lumborum block versus transversus abdominis plane block with liposomal bupivacaine: A case report. J Anesth Crit Care Open Access 2016;66:00214.

21. Stephan B, Ramshaw B, Forman B. Value-based clinical quality improvement (cqi) for patients undergoing abdominal wall reconstruction. Surg Technol Int 2015;26:135-42.

22. Ayad S, Babazade R, Elsharkawy H, Nadar V, Lokhande C, Makarova N, et al. Comparison of transversus abdominis plane infiltration with liposomal bupivacaine versus continuous epidural analgesia versus intravenous opioid analgesia. PLoS One 2016;11:1-15.

23. Ilfeld BM. Continuous peripheral nerve blocks: A review of the published evidence. Anesth Analg 2017;124:308-335.

24. Jeng CL, Torrillo TM, Rosenblatt MA. Complications of peripheral nerve blocks. Br J Anesth 2010;105:97-107.

25. Wikner M. Unexpected motor weakness following quadratus lumborum block for gynaecological laparoscopy. Anaesthesia 2017;72:230-2.

26. Lambrechts M, O’Brien MJ, Savoie FH, You Z. Liposomal extended-release bupivacaine for postsurgical analgesia. Patient Prefer Adherence 2013;7:885-90.